Danaher Corp

DHR: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$146.00BphcxsVsxcvfxb

Danaher Earnings: Bioprocessing Unit May Be Bottoming Amid Veralto Spinoff

Narrow-moat Danaher turned in solid third-quarter results, as its bioprocessing business appears to be bottoming near management expectations. At first blush, we do not anticipate changing near-term expectations or our $243 fair value estimate materially, which incorporates the Veralto spinoff. Danaher's shares remain moderately undervalued.

Sponsor Center